Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1998

View Archived Issues

Seattle Genetics initiates a phase I clinical trial of SGN-10

Phase II trials of Xenova's P-gp pump inhibitor planned in U.S. and U.K.

Vanguard drops hyperphosphatemia Rx from development pipeline

MedImmune and BioTransplant initiate two new clinical studies of MEDI-507

Merck KGaA prefers alliances to mergers; signs new deal with ImClone Systems

Neoprobe to develop product for intraoperative detection of neuroblastoma

FDA grants expedited development status to Cordox as it begins phase III trials

TerraGen and Schering-Plough Research Institute establish collaborative agreement

SmithKline Beecham and Ribi announce positive HBV phase III trial data

Dendreon presents phase I/II data on APC-8020 at ASH meeting

Eisai launches new formulation of antiarrhythmic drug in Japan

SonoRx studies presented at RSNA meeting; U.S. launch imminent

AMI-227: a novel contrast agent with several potential uses in MRI

New RES-specific contrast agents enter the pipeline at Bracco

News from RSNA 98: German team describes MRI contrast agent CMD-Gd-DOTA

Elastase inhibition as a potential approach to treating acute viral myocarditis

Angiotech initiates another clinical trial with paclitaxel for treatment of psoriasis

Tularik, Knoll to collaborate on antiobesity R&D

ISS-DNA alters the immune response and prevents symptoms of allergic asthma

New antidiabetic agents from Yamanouchi have a dual mechanism of action

PLA2 inhibitors with broad potential application as antiinflammatory agents

New agents for micturition disorders discovered at Kyowa Hakko

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...